0000899243-18-030260.txt : 20181206
0000899243-18-030260.hdr.sgml : 20181206
20181206164550
ACCESSION NUMBER: 0000899243-18-030260
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20181204
FILED AS OF DATE: 20181206
DATE AS OF CHANGE: 20181206
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: IVERS-READ GILLIAN C
CENTRAL INDEX KEY: 0001268304
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35347
FILM NUMBER: 181221208
MAIL ADDRESS:
STREET 1: C/O PHARMION CORPORATION
STREET 2: 2525 28TH STREET
CITY: BOULDER
STATE: CO
ZIP: 80301
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Clovis Oncology, Inc.
CENTRAL INDEX KEY: 0001466301
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 900475355
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 5500 FLATIRON PARKWAY
STREET 2: SUITE 100
CITY: BOULDER
STATE: CO
ZIP: 80301
BUSINESS PHONE: (303) 625-5000
MAIL ADDRESS:
STREET 1: 5500 FLATIRON PARKWAY
STREET 2: SUITE 100
CITY: BOULDER
STATE: CO
ZIP: 80301
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-12-04
0
0001466301
Clovis Oncology, Inc.
CLVS
0001268304
IVERS-READ GILLIAN C
C/O CLOVIS ONCOLOGY, INC.
5500 FLATIRON PARKWAY, SUITE 100
BOULDER
CO
80301
0
1
0
0
See Remarks
Common Stock
2018-12-04
4
M
0
625
A
186402
D
Common Stock
2018-12-04
4
S
0
250
21.23
D
186152
D
Restricted Stock Units
2018-12-04
4
M
0
625
0.00
D
Common Stock
625
5625
D
Each Restricted Stock Unit represents the right to receive one share of Common Stock.
Represents the shares automatically sold by the reporting person pursuant to an election to satisfy tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale does not represent a discretionary trade by the reporting person.
On March 27, 2017, the reporting person was granted 10,000 Restricted Stock Units. 25% of such Restricted Stock Units vested on March 1, 2018, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date.
Executive Vice President of Technical Operations and Chief Regulatory Officer
/s/ Gillian Ivers-Read
2018-12-05